Identification of blood lipid markers of docetaxel treatment in prostate cancer patients

Abstract Docetaxel is commonly used for treatment of castration-resistant prostate cancer. Unfortunately, many prostate cancer patients develop resistance to docetaxel. Clinical markers less invasive than biopsies, such as blood samples, would be ideal for monitoring and predicting patient treatment...

Descrición completa

Detalles Bibliográficos

Principais autores:	Morgan C. Finnerty, Franklin E. Leach, Yousef Zakharia, Kenneth G. Nepple, Michael G. Bartlett, Michael D. Henry, Brian S. Cummings
Formato:	Artigo
Idioma:	Inglês
Publicado:	Nature Portfolio 2024-09-01
Series:	Scientific Reports
Assuntos:	Docetaxel Prostate cancer Lipidomics Drug resistance Biomarker Clinical
Acceso en liña:	https://doi.org/10.1038/s41598-024-73074-8
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!